ATE361066T1 - Polyungesättigen fettsäuren nährungsergänzung - Google Patents

Polyungesättigen fettsäuren nährungsergänzung

Info

Publication number
ATE361066T1
ATE361066T1 AT99970319T AT99970319T ATE361066T1 AT E361066 T1 ATE361066 T1 AT E361066T1 AT 99970319 T AT99970319 T AT 99970319T AT 99970319 T AT99970319 T AT 99970319T AT E361066 T1 ATE361066 T1 AT E361066T1
Authority
AT
Austria
Prior art keywords
ara
dha
polyunsaturated fatty
fatty acid
nutritional supplement
Prior art date
Application number
AT99970319T
Other languages
German (de)
English (en)
Inventor
Waterschoot Isabel Antonia Van
Hugo Streekstra
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361066(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE361066T1 publication Critical patent/ATE361066T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
AT99970319T 1998-10-15 1999-10-15 Polyungesättigen fettsäuren nährungsergänzung ATE361066T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98308403 1998-10-15

Publications (1)

Publication Number Publication Date
ATE361066T1 true ATE361066T1 (de) 2007-05-15

Family

ID=8235104

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970319T ATE361066T1 (de) 1998-10-15 1999-10-15 Polyungesättigen fettsäuren nährungsergänzung

Country Status (13)

Country Link
US (2) US20070184090A1 (https=)
EP (4) EP1121115B2 (https=)
JP (2) JP2002527387A (https=)
CN (3) CN102090636A (https=)
AT (1) ATE361066T1 (https=)
AU (2) AU775421B2 (https=)
CA (2) CA2355341C (https=)
DE (1) DE69935995T3 (https=)
DK (1) DK1121115T4 (https=)
ES (1) ES2284286T5 (https=)
HK (1) HK1042441A1 (https=)
NZ (1) NZ511071A (https=)
WO (1) WO2000021524A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1911837B1 (en) 2000-09-28 2011-05-25 Bioriginal Food & Science Corp. FAD5-2 fatty acid desaturase family member and uses thereof
CA2442692A1 (en) 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU778384B2 (en) * 2001-11-14 2004-12-02 Virtus Nutrition Llc Method for manufacturing fatty acid calcium salts from high glyceride content oils
EP2255667A1 (en) * 2002-06-19 2010-12-01 DSM IP Assets B.V. Pasteurisation process for microbial cells and microbial oil
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
US20070037885A1 (en) * 2003-04-25 2007-02-15 Sandra Edwards Biomass containing animal feed
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
EA200602014A1 (ru) 2004-04-30 2007-08-31 ВИРТУС НЬЮТРИШН ЭлЭлСи Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот
JP5667737B2 (ja) * 2004-07-01 2015-02-12 ネステク ソシエテ アノニム イヌ変形性関節症食餌製剤
ES2253089B1 (es) * 2004-07-16 2007-08-16 Berthol Victor Laboratorios Ordesa, S.L. Complemento nutraceutico para la preparacion de leches infantiles.
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
EP2098229A4 (en) 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
WO2009102558A2 (en) * 2008-02-11 2009-08-20 Monsanto Technology Llc Aquaculture feed, products, and methods comprising beneficial fatty acids
CN101259101B (zh) * 2008-04-17 2010-06-02 湖北福星生物科技有限公司 微米级花生四烯酸和二十二碳六烯酸乳状液及其制备方法
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
EP3689342A1 (en) * 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
EP2745706A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Methods for maintaining bone quality
FI3626806T3 (fi) 2013-12-20 2024-08-22 Mara Renewables Corp Menetelmiä öljyn talteenottamiseksi mikro-organismeista
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
MX2022012322A (es) 2020-04-03 2022-11-10 Mara Renewables Corp Aceites microbianos con niveles altos de ácidos grasos omega-3.
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
AU2023337123A1 (en) * 2022-09-07 2025-04-03 Nourish Ingredients Pty Ltd Compositions and methods for producing meat-like aromas
WO2026020071A1 (en) * 2024-07-18 2026-01-22 Red Abbey Labs, Llc Autogenous therapeutic lipid carriers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
US5658767A (en) † 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
ES2157898T3 (es) 1991-01-24 2001-09-01 Martek Corp Aceites microbianos y usos de los mismos.
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
JPH0692848A (ja) * 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
JPH06271464A (ja) * 1993-03-19 1994-09-27 Tokiwa Yakuhin Kogyo Kk 消化器系障害の予防または治療用アラキドン酸含有組成物
PT707487E (pt) * 1993-06-09 2004-08-31 Martek Biosciences Corp Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos
JPH07267856A (ja) * 1994-02-09 1995-10-17 Green Cross Corp:The 経口免疫抑制剤
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
AU6252196A (en) * 1995-06-07 1996-12-30 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
ES2256882T5 (es) 1996-03-26 2012-12-17 Dsm Ip Assets B.V. Agregado tardío de pufa en el transcurso del proceso de preparación de una leche maternizada
EP0893953B1 (en) 1996-03-26 2002-06-05 Dsm N.V. Pufa coated solid carrier particles for foodstuff
JP4545235B2 (ja) 1996-03-28 2010-09-15 ディーエスエム アイピー アセッツ ビー．ブイ． 顆粒状微生物バイオマスの製造法とそのバイオマスからの貴重化合物の単離法
CN1217029A (zh) 1996-03-28 1999-05-19 吉斯特-布罗卡迪斯股份有限公司 从用巴氏法灭菌的生物量中制备含有微生物多不饱和脂肪酸的油的方法
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品

Also Published As

Publication number Publication date
JP2002527387A (ja) 2002-08-27
US20090105342A1 (en) 2009-04-23
DE69935995D1 (de) 2007-06-14
WO2000021524A1 (en) 2000-04-20
EP1803451A1 (en) 2007-07-04
EP1121115B1 (en) 2007-05-02
NZ511071A (en) 2004-01-30
DE69935995T3 (de) 2011-02-10
CA2355341A1 (en) 2000-04-20
CA2355341C (en) 2009-04-14
DE69935995T2 (de) 2008-01-10
AU2004224924A1 (en) 2004-11-25
DK1121115T3 (da) 2007-07-02
EP2292223A1 (en) 2011-03-09
CN102090636A (zh) 2011-06-15
DK1121115T4 (da) 2011-01-10
CA2653503A1 (en) 2000-04-20
AU1152000A (en) 2000-05-01
ES2284286T3 (es) 2007-11-01
EP1121115A1 (en) 2001-08-08
US20070184090A1 (en) 2007-08-09
JP2011098966A (ja) 2011-05-19
EP2308486A1 (en) 2011-04-13
CN101283807A (zh) 2008-10-15
AU2004224924B2 (en) 2008-02-28
HK1042441A1 (zh) 2002-08-16
AU775421B2 (en) 2004-07-29
ES2284286T5 (es) 2011-01-03
CN1326344A (zh) 2001-12-12
EP1121115B2 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
ATE361066T1 (de) Polyungesättigen fettsäuren nährungsergänzung
US5198468A (en) Essential fatty acid composition
US5562913A (en) Formulation for use in smokers
JP2796838B2 (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
CA2069600C (en) Fatty acid compositions
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
NZ505608A (en) Fat blend
KR900008958A (ko) 유아용 규정식품에 사용하기 위한 랜덤화된 야자유 지방 조성물
KR940018091A (ko) 불포화 지방산을 포함하는 처방
CA1310911C (en) Essential fatty acid compositions
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
EP1211305A4 (en) FAT COMPOSITIONS
SG143274A1 (en) Nutrition containing fat blend
EP0437524B1 (en) Triglyceride and nutritional composition comprising such triglycerides.
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
KR100270622B1 (ko) 영양보급용 영양 조성물
EP0211502A2 (en) Use of metabolites of linoleic or linolenic acid in the treatment of premenstrual syndrome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties